Source: Health Products Regulatory Authority (IE) Revision Year: 2013 Publisher: Aspen Pharma Trading Limited 3016 Lake Drive Citywest Business Campus Dublin 24 Ireland
Lanvis 40mg Tablets.
Pharmaceutical Form |
---|
Tablets. Lanvis Tablets are white to off white tablet, round, biconvex scored and imprinting ‘T40’ on upper side, without score and debossing on lower side. The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses. |
Tablet containing 40 mg tioguanine.
Excipients: Also contains 150mg Lactose Monohydrate
For a full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Tioguanine |
Tioguanine is a sulphydryl analogue of guanine and behaves as a purine antimetabolite. It is activated to its nucleotide, thioguanylic acid. Tioguanine metabolites inhibit de novo purine synthesis and purine nucleotide interconversions. Tioguanine is also incorporated into nucleic acids and DNA (deoxyribonucleic acid) incorporation is claimed to contribute to the agent’s cytotoxicity. |
List of Excipients |
---|
Lactose monohydrate |
Lanvis tablets are supplied in amber (Type III) glass bottles with a polypropylene/HDPE child-resistant closure, containing 25 tablets.
Aspen Pharma Trading Limited
3016 Lake Drive
Citywest Business Campus
Dublin 24
Ireland
PA 1691/6/1
Date of first authorisation: 1 April 1979
Date of last renewal: 1 April 2009
Drug | Countries | |
---|---|---|
LANVIS | Australia, Brazil, Canada, Estonia, France, Hong Kong, Ireland, Lithuania, Netherlands, New Zealand, Poland, Romania, Turkey, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.